CordenPharma Group, the global pharmaceutical service and manufacturing platform of International Chemical Investors Group (ICIG), is pleased to announce the appointment of Dr Michael Quirmbach as Chief Executive Officer and President, effective 1 August 2019.
Michael Quirmbach joined CordenPharma Group in October 2014 as Chief Business Officer and has been a member of the Executive Leadership Team.
Since then, he has been instrumental in establishing CordenPharma in the market as a reputable, trustworthy and world-class CDMO to the pharmaceutical industry.
Prior to joining CordenPharma, Michael Quirmbach held several management positions in the CDMO and biotech industry with companies such as Siegfried, Dr. Reddy’s and Solvias.
He holds a degree in chemistry and a PhD from the Max Planck Research Group at the Institute for Organic Catalysis Research in Rostock (DE), as well as an MBA from La Salle University in Philadelphia (USA).
The Executive Leadership Team of CordenPharma Group will consist of Dr Michael Quirmbach as CEO and President, Dr Walter Kittl as COO, together with Heiko Serwe, CFO, and Dr Esua Macniell, Chief Compliance Officer.
“We thank Riku Rautsola for taking the responsibility of CordenPharma at a critical time and are pleased with the appointment of Michael Quirmbach as our new CEO and President of CordenPharma Group," stated Dr Achim Riemann and Patrick Schnitzer, Managing Directors of ICIG.
"Michael Quirmbach has demonstrated strong leadership and was instrumental in CordenPharma’s continued growth trajectory during the last few years to become a major CDMO player to the pharmaceutical industry."
Our leadership team is now well positioned to accelerate plans for long-term growth. We are also pleased that Riku will continue to support ICIG and CordenPharma Group as a Senior Adviser to the Executive Leadership Team,” they concluded.
